OXGENE combines precision engineering, biology, robotics and bioinformatics to accelerate the design, discovery and manufacture of biologics across gene therapy, gene editing and antibody therapeutics. The company has collaborated with global partners including Abcam, Artios Pharma and The Native Antigen Company, and has signed eight separate licence agreements to provide access to its technology. OXGENE recently announced a strategic partnership with FUJIFILM Diosynth Biotechnologies to support partners in development and production of biologics, vaccines and gene therapies. Management says the company has more than doubled its revenue in the most recent financial year while increasing headcount by less than 50%, which it attributes to its automation platform and focused business development. The firm positions itself to address growing market demand in synthetic biology and to bring additional technologies to market through partnerships and licensing. Mercia highlights OXGENE’s recognition by large pharmaceutical brands and the company’s potential to deliver medium- to long-term value. Oxford Genetics develops synthetic biology-based tools and services for biologics discovery, development and delivery, including versatile cloning plasmids, custom cloning and DNA synthesis. The company serves academic and biotechnology institutions and has seen growth in clients, key appointments and momentum in cell and gene therapy markets. It has signed multiple licenses, entered two collaborative partnerships with gene therapy companies, and filed five new patents to extend its IP. Led by CEO Ryan Cawood, Oxford Genetics plans to use new funding to expand its physical footprint and R&D capabilities. Planned uses include opening a Boston office and extending its UK facility at Oxford Science Park by November 2017 with cell line engineering, viral vector production and purification suites, high-throughput robotic screening, and process development facilities. The company also intends to invest in R&D to grow its intellectual property portfolio and scale a technology-enabled licensing business. Oxford Genetics focuses on DNA design, with expertise in protein expression optimisation and cell line development. It provides bespoke solutions aimed at research, therapeutic and clinical needs within the pharmaceutical sector. The company's core offerings center on optimising protein expression and developing tailored cell lines for customers. Mercia Technologies has announced a new direct investment of up to £2.0 million in Oxford Genetics Ltd. The announcement was published as a stock exchange announcement and links to the Oxford Genetics website are provided. No operating metrics or additional financial details are disclosed in the article. Oxford Genetics, led by CEO Dr Ryan Cawood, develops SnapFast™, a system that simplifies purchasing synthetic DNA plasmids. The company currently supplies human, mouse and bacterial DNA. Through the new funding it plans to expand offerings to include insect, plant and yeast DNA. It received £150K in funding from Mercia Fund Management. The proceeds will be used to build an e-commerce website and support new product development. The company is based in Oxford, UK.

Total raised

$16M

Funding rounds

4

Latest round

Equity

Latest activity

May 2020